
|Articles|February 24, 2014 (Updated: April 18, 2020)
- Gastrointestinal Cancers (Issue 1)
- Volume 1
- Issue 1
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Author(s)Robert L. Fine, MD
Robert L. Fine, MD, from Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer.
Robert L. Fine, MD, associate professor of medicine, Herbert Irving, director, Experimental Therapeutics, medical oncology director, Pancreas Center, Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer.
Read more abouta hedgehog pathway inhibitor for the treatment of advanced pancreatic cancer > >
Articles in this issue
about 12 years ago
The Identification of Molecular Subtypes of Gastric Cancerabout 12 years ago
Ramucirumab Combo Increases Survival in Gastric Cancerabout 12 years ago
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Dataabout 12 years ago
New Standard of Neoadjuvant Care for Rectal Cancer Establishedabout 12 years ago
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancerabout 12 years ago
The Treatment of Advanced Colorectal Cancerabout 12 years ago
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCCRelated Content
Advertisement


Safety and Antitumor Activity Revealed for T-Cell Engager XmAb819 in RCC
Published: | Updated:

Sarcomatoid Features May Be a Biomarker in Chromophobe RCC
Published: | Updated:

Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma
Published: | Updated:




























